REGN

Regeneron Pharmaceuticals Stock (NASDAQ: REGN)

Regeneron Pharmaceuticals Stock (NASDAQ:REGN), Trade Ideas

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

abbvie shutter

Biotech

Large Cap

News

Health Care

General

ABBV

AbbVie&#39;s Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficacy and rapid skin clearance than Dupixent.

AbbVie&#39;s Dermatitis Drug Shown &#39;Superior&#39; To Sanofi/Regeneron&#39;s Dupixent In Head-To-Head Study

Doctor,Examining,A,Lung,Radiography

Analyst Color

Equities

Reiteration

Analyst Ratings

Trading Ideas

AMGN

Amgen&#39;s Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts ≥150 cells/μL and ≥300 cells/μL.

Amgen/AstraZeneca&#39;s Asthma Drug Tezspire Vs. Sanofi/Regeneron&#39;s Blockbuster Dupixent - Analyst Gives His Pick

Legal

The U.S. Justice Department accuses Regeneron Pharmaceuticals of Medicare fraud related to its macular degeneration drug, Eylea. Allegations include manipulating drug prices, resulting in inflated Medicare expenses.

Eye Drug Eylea Price Manipulation: Regeneron Faces US Justice Department Allegations Over Medicare Pricing Of Its Best-Selling Eye Drug

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals Inc

Regnum Corp

Thursday,&nbsp;AbbVie&nbsp;Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NASDAQ">ABBV</a>) released topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase&nbsp;3b/4&nbsp;study of upadacitinib (Rinvoq, 15 mg once daily starting dose and dose-adjusted based on clinical response) versus dupilumab (Dupixent, per its labeled dose)&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/n38428188/new-data-show-rinvoq-upadacitinib-demonstrated-superiority-versus-dupixent-dupilumab-across-primar" rel="noreferrer noopener">for atopic dermatitis</a>.
AbbVie said the study is the first head-to-head trial in atopic dermatitis assessing upadacitinib at a starting&nbsp;dose of 15 mg daily versus dupilumab at its labeled dose.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38300021/is-your-botox-real-or-fake-counterfeit-boxes-circulate-for-widely-used-antiwrinkle-treatment-cdc-" rel="noreferrer noopener">Is Your Botox Real Or Fake? Counterfeit Boxes Circulate For Widely Used Antiwrinkle Treatment, CDC And FDA Investigate Harmful Reactions</a>.
The study enrolled adults and adolescents with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to systemic therapy or when the use of those therapies was inadvisable.
Dupixent is the flagship drug of&nbsp;Sanofi SA&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) and&nbsp;Regeneron&nbsp;Pharmaceutical Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>).
In the study,&nbsp;upadacitinib showed superior efficacy versus dupilumab in the primary endpoint, demonstrating that a significantly higher proportion of patients simultaneously achieved both a 90% or&nbsp;greater&nbsp;reduction in Eczema Area and Severity Index (EASI 90) and a Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 16.
<ul>
<li>Rinvoq helped 19.9% of patients achieve 90% skin clearance with a no-to-little itch, compared with 8.9% of patients treated with Dupixent.</li>
<li>The EASI is a clinically validated measure used to assess the severity and extent of atopic dermatitis.&nbsp;</li>
<li>WP-NRS is an assessment tool that patients use to report the intensity of their pruritus daily (with 0 being &#8216;no itch&#8217; and 10 being the &#8216;worst imaginable itch&#8217;).</li>
</ul>
Upadacitinib also showed superiority over dupilumab for all ranked secondary endpoints, including the rapid onset of nearly complete skin clearance and little to little itch.&nbsp;
For the first two ranked secondary endpoints, the study showed that&nbsp;a significantly higher proportion of patients treated with upadacitinib:
<ul>
<li>Achieved EASI 90 at Week 16 (40.8% vs 22.5%).</li>
<li>Achieved a WP-NRS of 0/1 at Week 16 (30.2% vs 15.5%).</li>
</ul>
Price Action: ABBV shares were down 0.15% at $167.54 at the last check Thursday.
Now Read: <a href="https://www.benzinga.com/markets/equities/24/04/38436183/magnificent-7-tumble-wipe-out-300-billion-on-metas-weak-guidance-q1-stagflation-woes">Magnificent 7 Tumble, Wipe Out $300 Billion On Meta&#8217;s Weak Guidance, Q1 Stagflation Woes</a>
Photo: Shutterstock

AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study

Under the terms of the agreement, Mammoth will receive&nbsp;$100 million&nbsp;inclusive of&nbsp;$95 million&nbsp;in equity investment at signing, and an upfront payment, and is eligible to receive up to&nbsp;$370 million&nbsp;per target in development, regulatory and commercial milestone payments, and royalty rates ranging from single digits to mid-teens on future net sales of all collaboration products.

Contracts

Regeneron, Mammoth Partner To Pursue Next-Generation CRISPR-Based Gene Editing For Multiple Diseases; Mammoth To Receive $100M Total Upfront Payment And Equity Investment

TD Cowen analyst Tyler Van Buren maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Buy and raises the price target from $1020 to $1030.

Price Target

TD Cowen Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1030

Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the treatment of certain advanced solid tumors in combination with Libtayo&#xAE; (cemiplimab-rwlc) &nbsp;
17 presentations to highlight Regeneron's investigational pipeline including checkpoint inhibitors, CD3 bispecifics and CD28 costimulatory bispecifics
TARRYTOWN, N.Y., April 24, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) today announced new and updated data from its oncology and hematology pipeline will be shared across 17 presentations at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place from May 31 to June 5 in Chicago, IL. Notably, new safety and efficacy results from a Phase 1/2 trial investigating the costimulatory bispecific antibody REGN7075 (EGFRxCD28) in combination with Libtayo in patients with certain advanced solid tumors will be featured in an oral presentation.
"The breadth of our presentations at ASCO showcase our progress in advancing multiple promising and distinct investigational treatment approaches for a diverse array of difficult-to-treat cancers," said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron. "These latest clinical results build on our ongoing commitment to cancer research and reflect our focus on advancing a pipeline of internally-developed candidates that have the potential to offer novel and differentiated therapies. Poised to tackle more than 30 types of cancer, our oncology pipeline is a testament to Regeneron's relentless commitment to transforming cancer care for those who need it most."
Beyond the REGN7075 data, additional presentations will feature results from Regeneron's diverse pipeline of checkpoint inhibitors and bispecific antibodies. Among them are presentations on updated data and new analyses for linvoseltamab (BCMAxCD3) in multiple myeloma; odronextamab (CD20xCD3) in several lymphoma subtypes; REGN6569 (GITR) in combination with Libtayo across solid tumors; and fianlimab (LAG-3 inhibitor) in combination with Libtayo in non-small cell lung cancer, melanoma and head and neck cancer.
Regeneron presentations at ASCO:&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Medicine&nbsp;</td>
<td>Abstract title&nbsp;</td>
<td>Abstract&nbsp;</td>
<td>Lead author&nbsp;</td>
<td>Presentation date/time&nbsp; (all CDT)&nbsp;</td>
</tr>
<tr>
<td colspan="5">Solid Tumor Malignancies&nbsp;</td>
</tr>
<tr>
<td>REGN7075, Libtayo &nbsp;</td>
<td>A Phase 1/2 study of REGN7075 in combination with cemiplimab in patients with advanced solid tumors: Updated dose escalation results&nbsp;</td>
<td>#2503&nbsp; Oral Presentation&nbsp; Session— Developmental Therapeutics—Immunotherapy&nbsp;</td>
<td>Segal, N.H.&nbsp;</td>
<td>Monday, June 3&nbsp; 11:30 a.m. – 2:30 p.m.&nbsp;</td>
</tr>
<tr>
<td>REGN6569, Libtayo&nbsp; &nbsp;</td>
<td>A Phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results&nbsp;</td>
<td>#2650&nbsp; Poster Presentation&nbsp; Session— Developmental Therapeutics—Immunotherapy&nbsp;</td>
<td>Lakhani, N.J.&nbsp;</td>
<td>Saturday, June 1&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
<tr>
<td colspan="5">Blood Cancer&nbsp;</td>
</tr>
<tr>
<td>Linvoseltamab&nbsp;</td>
<td>Indirect comparison of linvoseltamab (linvo) versus teclistamab (tec) for treatment of triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)&nbsp;&nbsp;&nbsp;</td>
<td>#7560&nbsp; Poster Presentation&nbsp; Session— Hematologic Malignancies—Plasma Cell Dyscrasia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Jagannath, S.&nbsp;</td>
<td>Monday, June 3&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
<tr>
<td>Linvoseltamab&nbsp;</td>
<td>Comparative effectiveness of linvoseltamab (Linvo) vs. standard of care (SOC) in real-world patients (pts) with triple class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)&nbsp;&nbsp;&nbsp;</td>
<td>#7561&nbsp; Poster Presentation&nbsp; Session— Hematologic Malignancies—Plasma Cell Dyscrasia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Kumar, S.&nbsp;</td>
<td>Monday, June 3&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
<tr>
<td>Odronextamab&nbsp;</td>
<td>Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator's choice in previously untreated follicular lymphoma (OLYMPIA-1)&nbsp;&nbsp;&nbsp;</td>
<td>#7096&nbsp; Poster Presentation&nbsp; Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia&nbsp; &nbsp;</td>
<td>Birhiray, R.&nbsp;</td>
<td>Monday, June 3&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
<tr>
<td>Odronextamab&nbsp;</td>
<td>Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2)&nbsp;</td>
<td>#7099&nbsp; Poster Presentation&nbsp; Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia&nbsp; &nbsp;</td>
<td>Hardin, C.&nbsp;</td>
<td>Monday, June 3&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
<tr>
<td>Odronextamab &nbsp;</td>
<td>Phase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL; OLYMPIA-3)&nbsp;</td>
<td>#7086 Poster Presentation&nbsp; Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia&nbsp; &nbsp;</td>
<td>Matasar, M.&nbsp;</td>
<td>Monday, June 3&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
<tr>
<td>Odronextamab&nbsp;</td>
<td>Phase 3 trial evaluating the efficacy and safety of odronextamab versus standard-of-care (SOC) therapy in relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL;OLYMPIA-4)&nbsp;</td>
<td>#7093&nbsp; Poster Presentation&nbsp; Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia&nbsp;</td>
<td>Hawkes, E.A.&nbsp;</td>
<td>Monday, June 3&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
<tr>
<td>Odronextamab &nbsp;</td>
<td>Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal one lymphoma (MZL; (OLYMPIA-5)&nbsp;</td>
<td>#7094&nbsp; Poster Presentation&nbsp; Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia&nbsp;</td>
<td>Vitolo, U.</td>
<td>Monday, June 3&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
<tr>
<td>Odronextamab&nbsp;</td>
<td>Results from the follicular lymphoma (FL) outcomes in relapsed/refractory (R/R) patients treated with systemic therapy in a real-world assessment (FLORA) study&nbsp;&nbsp;&nbsp;</td>
<td>#7076&nbsp; Poster Presentation&nbsp; Session— Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia&nbsp;</td>
<td>Luminari, S.&nbsp;</td>
<td>Monday, June 3&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
<tr>
<td colspan="5">Skin Cancer&nbsp;</td>
</tr>
<tr>
<td>Fianlimab, Libtayo&nbsp;</td>
<td>A Phase 3 trial of fixed dose combinations of fianlimab (anti-LAG-3) + cemiplimab (anti-PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma&nbsp;</td>
<td>#TPS9611&nbsp; Poster Presentation&nbsp; Session— Melanoma/Skin Cancers&nbsp;</td>
<td>Khushalani, N.I.&nbsp;</td>
<td>Saturday, June 1&nbsp; 1:30 p.m. – 4:30 p.m.&nbsp;</td>
</tr>
<tr>
<td colspan="5">Lung Cancer&nbsp;</td>
</tr>
<tr>
<td>Fianlimab, Libtayo</td>
<td>A Phase 2/3 study of fianlimab, cemiplimab, plus chemotherapy versus cemiplimab plus chemotherapy in first-line advanced non-small cell lung cancer&nbsp;&nbsp;&nbsp;</td>
<td>#TPS8660&nbsp; Poster Presentation&nbsp; Session— Lung Cancer—Non-Small Cell Metastatic&nbsp;</td>
<td>Gabrail, N.&nbsp;</td>
<td>Monday, June 3&nbsp; 1:30 p.m. – 4:30 p.m&nbsp;&nbsp;</td>
</tr>
<tr>
<td>Fianlimab, Libtayo&nbsp;</td>
<td>A Phase 2/3 study of fianlimab plus cemiplimab versus cemiplimab in patients with advanced non-small cell lung cancer with tumors expressing PD-L ≥50%&nbsp;</td>
<td>#TPS8663&nbsp; Poster Presentation&nbsp; Session— Lung Cancer—Non-Small Cell Metastatic&nbsp;</td>
<td>Faulkner, N.&nbsp;</td>
<td>Monday, June 3&nbsp; 1:30 p.m. – 4:30 p.m.&nbsp; &nbsp;</td>
</tr>
<tr>
<td colspan="5">Gynecologic Cancer&nbsp;&nbsp;</td>
</tr>
<tr>
<td>Libtayo&nbsp;</td>
<td>Combination of cemiplimab and ISA101b vaccine for the treatment of recurrent/metastatic HPV16 cervical cancer&#x2A;&nbsp;</td>
<td>#5522&nbsp; Poster Presentation&nbsp; Session— Gynecologic Cancer&nbsp;&nbsp;</td>
<td>Lorusso, D.&nbsp;</td>
<td>Monday, June 3&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
<tr>
<td>Ubamatamab, Libtayo&nbsp;</td>
<td>A Phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti–PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer: Trial in progress update&nbsp;</td>
<td>#TPS5632&nbsp; Poster Presentation&nbsp; Session— Gynecologic Cancer&nbsp;</td>
<td>Nieuwenhuysen, E.&nbsp;</td>
<td>Monday, June 3&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
<tr>
<td colspan="5">Head and Neck Cancer&nbsp;</td>
</tr>
<tr>
<td>Fianlimab, Libtayo</td>
<td>A Phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced HNSCC&nbsp;</td>
<td>#6038&nbsp; Poster Presentation&nbsp; Session— Head and Neck Cancer&nbsp;</td>
<td>Cho, B.C.&nbsp;</td>
<td>Sunday, June 2&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
<tr>
<td>DB-020&nbsp;</td>
<td>A phase 1 clinical trial of DB-020 intratympanic injections administered prior to high dose cisplatin chemotherapy to reduce ototoxicity&nbsp;</td>
<td>#6100 Poster Presentation&nbsp; Session— Head and Neck Cancer&nbsp;</td>
<td>Rischin, D.&nbsp;</td>
<td>Sunday, June 2&nbsp; 9:00 a.m. – 12:00 p.m.&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
&#x2A;Study conducted in collaboration between Regeneron and ISA.
The potential uses of Libtayo, REGN7075, odronextamab, linvoseltamab, REGN6569, fianlimab and DB-020 as described above are investigational, and their safety and efficacy in these uses have not been fully evaluated by any regulatory authority. REGN7075, odronextamab, linvoseltamab, REGN6569, fianlimab and DB-020 are not currently approved for use in any indication.&nbsp;

Regeneron To Showcase Progress In Advancing Novel Investigational Treatment Approaches For A Broad Range Of Solid Tumors And Blood Cancers At ASCO

ata from 10 abstracts, including six oral presentations, provide insight on Regeneron&#39;s approach to overcoming obstacles to clinical implementation of genetic medicines, from pre-dosing to delivery to long-term sustained expression. The company will also present updated data from the Phase 1/2 CHORD trial investigating DB-OTO in children with profound genetic hearing loss due to mutations of the otoferlin gene.

Regeneron To Present New And Updated Data Across Its Genetic Medicines Portfolio At ASGCT Annual Conference

In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) against its key competitors in the Biotechnology industry. By analyzing important financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.
<h3>Regeneron Pharmaceuticals Background</h3>
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regeneron Pharmaceuticals Inc</td>
<td>25.93</td>
<td>3.81</td>
<td>7.81</td>
<td>4.56%</td>
<td>$1.28</td>
<td>$2.92</td>
<td>0.58%</td>
</tr>
<tr>
<td>AbbVie Inc</td>
<td>60.39</td>
<td>28.07</td>
<td>5.36</td>
<td>6.94%</td>
<td>$3.85</td>
<td>$8.6</td>
<td>-5.42%</td>
</tr>
<tr>
<td>Amgen Inc</td>
<td>21.14</td>
<td>22.71</td>
<td>5.04</td>
<td>11.05%</td>
<td>$3.05</td>
<td>$5.08</td>
<td>19.84%</td>
</tr>
<tr>
<td>Vertex Pharmaceuticals Inc</td>
<td>28.30</td>
<td>5.78</td>
<td>10.38</td>
<td>5.68%</td>
<td>$1.22</td>
<td>$2.15</td>
<td>9.34%</td>
</tr>
<tr>
<td>Gilead Sciences Inc</td>
<td>14.88</td>
<td>3.66</td>
<td>3.11</td>
<td>6.33%</td>
<td>$2.59</td>
<td>$5.02</td>
<td>-3.72%</td>
</tr>
<tr>
<td>Biogen Inc</td>
<td>24.10</td>
<td>1.89</td>
<td>2.84</td>
<td>1.71%</td>
<td>$0.5</td>
<td>$1.77</td>
<td>-6.2%</td>
</tr>
<tr>
<td>BioNTech SE</td>
<td>21.24</td>
<td>0.97</td>
<td>5.17</td>
<td>2.28%</td>
<td>$0.46</td>
<td>$1.3</td>
<td>-65.43%</td>
</tr>
<tr>
<td>Genmab A/S</td>
<td>30.31</td>
<td>4.11</td>
<td>8.01</td>
<td>2.04%</td>
<td>$0.93</td>
<td>$4.55</td>
<td>-8.94%</td>
</tr>
<tr>
<td>Biomarin Pharmaceutical Inc</td>
<td>103.99</td>
<td>3.47</td>
<td>7.16</td>
<td>0.41%</td>
<td>$0.05</td>
<td>$0.51</td>
<td>20.22%</td>
</tr>
<tr>
<td>Neurocrine Biosciences Inc</td>
<td>54</td>
<td>6.01</td>
<td>7.14</td>
<td>6.98%</td>
<td>$0.2</td>
<td>$0.51</td>
<td>25.05%</td>
</tr>
<tr>
<td>Incyte Corp</td>
<td>19.89</td>
<td>2.28</td>
<td>3.22</td>
<td>3.97%</td>
<td>$0.29</td>
<td>$0.94</td>
<td>9.35%</td>
</tr>
<tr>
<td>United Therapeutics Corp</td>
<td>11.88</td>
<td>1.85</td>
<td>5.02</td>
<td>3.71%</td>
<td>$0.32</td>
<td>$0.54</td>
<td>25.07%</td>
</tr>
<tr>
<td>Roivant Sciences Ltd</td>
<td>1.98</td>
<td>1.38</td>
<td>68.09</td>
<td>144.81%</td>
<td>$5.11</td>
<td>$0.03</td>
<td>117.8%</td>
</tr>
<tr>
<td>Exelixis Inc</td>
<td>35.19</td>
<td>3.06</td>
<td>4.02</td>
<td>3.71%</td>
<td>$0.09</td>
<td>$0.46</td>
<td>13.15%</td>
</tr>
<tr>
<td>Average</td>
<td>32.87</td>
<td>6.56</td>
<td>10.35</td>
<td>15.36%</td>
<td>$1.44</td>
<td>$2.42</td>
<td>11.55%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>By conducting an in-depth analysis of Regeneron Pharmaceuticals, we can identify the following trends: 
<ul>
<li>
With a Price to Earnings ratio of 25.93, which is 0.79x less than the industry average, the stock shows potential for growth at a reasonable price, making it an interesting consideration for market participants.
</li>
<li>
The current Price to Book ratio of 3.81, which is 0.58x the industry average, is substantially lower than the industry average, indicating potential undervaluation.
</li>
<li>
With a relatively low Price to Sales ratio of 7.81, which is 0.75x the industry average, the stock might be considered undervalued based on sales performance.
</li>
<li>
The company has a lower Return on Equity (ROE) of 4.56%, which is 10.8% below the industry average. This indicates potential inefficiency in utilizing equity to generate profits, which could be attributed to various factors.
</li>
<li>
The company has lower Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $1.28 Billion, which is 0.89x below the industry average. This potentially indicates lower profitability or financial challenges.
</li>
<li>
Compared to its industry, the company has higher gross profit of $2.92 Billion, which indicates 1.21x above the industry average, indicating stronger profitability and higher earnings from its core operations.
</li>
<li>
The company's revenue growth of 0.58% is significantly below the industry average of 11.55%. This suggests a potential struggle in generating increased sales volume.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713452445_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio provides insights into the proportion of debt a company has in relation to its equity and asset value.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
In terms of the Debt-to-Equity ratio, Regeneron Pharmaceuticals stands in comparison with its top 4 peers, leading to the following comparisons:
<ul>
<li>
Regeneron Pharmaceuticals is in a relatively stronger financial position compared to its top 4 peers, as evidenced by its lower debt-to-equity ratio of 0.1.
</li>
<li>
This implies that the company relies less on debt financing and has a more favorable balance between debt and equity.
</li>
</ul>
<h3>Key Takeaways</h3>
For Regeneron Pharmaceuticals, the PE, PB, and PS ratios are all low compared to its peers in the Biotechnology industry, indicating potential undervaluation. However, the low ROE and EBITDA suggest lower profitability and operational efficiency. On the positive side, the company has a high gross profit margin, which is favorable. The low revenue growth rate may be a concern for future performance compared to industry peers.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Markets

Market Analysis: Regeneron Pharmaceuticals And Competitors In Biotechnology Industry

Tuesday,&nbsp;Amgen Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) provided an update regarding the results of the Phase 2a COURSE trial for Tezspire (tezepelumab-ekko) in chronic obstructive&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/n38282098/amgen-to-present-tezspire-phase-2a-copd-data-at-ats-2024" rel="noreferrer noopener">pulmonary disease (COPD)</a>.&nbsp;
Tezspire is a registered trademark of Amgen and&nbsp;AstraZeneca Plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>).
<ul>
<li>Overall, tezepelumab numerically reduced the annualized rate of moderate or severe COPD exacerbations versus placebo by 17%, although the reduction was not statistically significant, with p=0.1042.&nbsp;</li>
<li>More reductions were observed in a prespecified subgroup of patients with baseline eosinophil count (BEC) ≥150 cells/μL (37%).</li>
<li>The trend in reduction was greater in a small number of subjects with BEC ≥300 cells/µL.&nbsp;</li>
</ul>
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37991995/amgens-diversified-portfolio-to-drive-long-term-growth-though-uncertainties-loom-an" rel="noreferrer noopener">Amgen&#8217;s Diversified Portfolio To Drive Long-Term Growth, Though Uncertainties Loom, Analyst Says</a>.
William Blair&nbsp;compared Tezspire&#8217;s results with&nbsp;Sanofi SA&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) and&nbsp;Regeneron Pharmaceutical Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Dupixent, demonstrating a 30% and 34% decrease in annualized moderate or severe acute COPD exacerbations in their Phase 3 studies.&nbsp;
However, Dupixent trials specifically enrolled patients with elevated blood eosinophils (≥300 cells/μL) at baseline, known to be linked with higher COPD exacerbation rates.&nbsp;
Tezspire&#8217;s trials indicated at least a 37% reduction in exacerbations for patients with eosinophil counts ≥150 cells/μL and ≥300 cells/μL, potentially offering greater benefits than Dupixent for this subset of patients.&nbsp;
This positive outcome in COPD could significantly expand Tezspire&#8217;s market beyond asthma, especially considering its successful commercial launch in 2021.&nbsp;
Investor interest in targeted therapies for COPD has risen due to Dupixent&#8217;s success, and Tezspire&#8217;s efficacy in a broader patient subset (150 cells/μL versus 300 cells/μL baseline eosinophil counts for Dupixent) is promising.&nbsp;
While awaiting the full dataset, the indication of a positive trend across all patients suggests further market opportunities for Tezspire.
The analyst keeps the&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/AMGN/analyst-ratings" rel="noreferrer noopener">Market Perform rating for the stock.</a>
Price Action: AMGN shares are up 0.06% at $265.80 on the last check Wednesday.
Photo by Minerva Studio via Shutterstock

Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick

Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) has outperformed the market over the past 20 years by 14.99% on an annualized basis producing an average annual return of 22.65%. Currently, Regeneron Pharmaceuticals has a market capitalization of $99.62 billion. 
Buying $100 In REGN: If an investor had bought $100 of REGN stock 20 years ago, it would be worth $6,678.66 today based on a price of $907.63 for REGN at the time of writing.
<h3>Regeneron Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713373238_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 20 Years Ago, You Would Have $6,700 Today

Cantor Fitzgerald analyst Olivia Brayer reiterates Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Neutral and maintains $925 price target.

Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $925 Price Target

Cantor Fitzgerald analyst Louise Chen reiterates Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Neutral and maintains $925 price target.

13 analysts have expressed a variety of opinions on Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $1072.38, a high estimate of $1189.00, and a low estimate of $720.00. This upward trend is evident, with the current average reflecting a 6.11% increase from the previous average price target of $1010.67.
<img src="https://www.benzinga.com/files/images/story/2024/1712930507_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Regeneron Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$720.00</td>
<td>$710.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1189.00</td>
<td>-</td>
</tr>
<tr>
<td>Robyn Karnauskas</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$1135.00</td>
<td>$1135.00</td>
</tr>
<tr>
<td>Robyn Karnauskas</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$1135.00</td>
<td>$1135.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1115.00</td>
<td>$1104.00</td>
</tr>
<tr>
<td>William Pickering</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$1125.00</td>
<td>-</td>
</tr>
<tr>
<td>Aaron Gal</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$1125.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1184.00</td>
<td>$1096.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$925.00</td>
<td>$850.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1110.00</td>
<td>$1076.00</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1082.00</td>
<td>$1055.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1076.00</td>
<td>-</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1020.00</td>
<td>$935.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Regeneron Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Regeneron Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Regeneron Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Regeneron Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/REGN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Regeneron Pharmaceuticals analyst ratings.</a>
<h2>All You Need to Know About Regeneron Pharmaceuticals</h2>
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
<h3>Breaking Down Regeneron Pharmaceuticals's Financial Performance</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Regeneron Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 0.58%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 33.77%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Regeneron Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 4.56%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Regeneron Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 3.55%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.1.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Regeneron Pharmaceuticals: 13 Analysts Share Their Views

B of A Securities analyst Geoff Meacham maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Underperform and raises the price target from $710 to $720.

B of A Securities Maintains Underperform on Regeneron Pharmaceuticals, Raises Price Target to $720

The U.S. Justice Department has leveled allegations against&nbsp;Regeneron Pharmaceuticals&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), accusing the company of manipulating Medicare&#8217;s drug-pricing system for its macular degeneration drug, Eylea (aflibercept).&nbsp;
In a federal court complaint filed in Boston, the department claims that Regeneron inflated the average sales price of Eylea, a move that significantly impacted Medicare expenses.
According to the lawsuit, Reuters highlighted that Regeneron purportedly failed to disclose substantial payments to drug distributors to subsidize Eylea&#8217;s purchases.&nbsp;
These payments ensured that distributors accepted credit card payments for the drug while offering lower prices to physicians and retina practices.
Related:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/37316706/median-drug-prices-for-rare-diseases-hit-300k-in-2023-report-highlights-lack-of-clear-rationale-b" rel="noreferrer noopener">Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices</a>.
Eylea is approved by the FDA for treating various eye-related conditions, including wet age-related macular degeneration.
In 2023, Regeneron recorded Eylea HD and Eylea US&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/36912319/why-is-sanofi-partner-regeneron-pharmaceuticals-stock-trading-higher-today" rel="noreferrer noopener">sales of $5.9 billion</a>.
The medication, with a wholesale acquisition cost of $1,850 per vial, has been a significant expense for Medicare, amounting to over $25 billion in payments from 2012 to 2023.&nbsp;
The lawsuit alleges that Regeneron&#8217;s failure to report all price concessions for Eylea violates the False Claims Act, resulting in inflated Medicare costs.
Acting U.S. Attorney Joshua Levy of Massachusetts emphasized that Regeneron&#8217;s actions greatly inflated Medicare costs and boosted its revenues.
Another ongoing lawsuit from 2020 accused the company of using a charity to pay kickbacks for Eylea usage among Medicare patients, an accusation Regeneron denies.
The current case originated from a whistleblower lawsuit filed in 2020 by former Regeneron employees operating under the False Claims Act, which allows whistleblowers to sue on behalf of the government to recover funds based on false claims.&nbsp;
Read Next:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37917335/fda-delays-decision-for-regenerons-inaugural-blood-cancer-therapy-highlights-trial-concerns" rel="noreferrer noopener">FDA Delays Decision For Regeneron&#8217;s Inaugural Blood Cancer Therapy, Highlights Trial Concerns</a>.
Price Action:&nbsp;REGN shares are down 1.44% at $922.75 on the last check Thursday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Investors with a lot of money to spend have taken a bearish stance on Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with REGN, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 12 uncommon options trades for Regeneron Pharmaceuticals.
This isn't normal.
The overall sentiment of these big-money traders is split between 16% bullish and 83%, bearish.
Out of all of the special options we uncovered, 8 are puts, for a total amount of $529,438, and 4 are calls, for a total amount of $126,443.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $660.0 to $1200.0 for Regeneron Pharmaceuticals over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Regeneron Pharmaceuticals's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Regeneron Pharmaceuticals's whale trades within a strike price range from $660.0 to $1200.0 in the last 30 days. 
<h3>Regeneron Pharmaceuticals Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1712852160_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$31.5</td>
<td>$30.0</td>
<td>$30.0</td>
<td>$885.00</td>
<td>$150.0K</td>
<td style="text-align: right;">27</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$55.2</td>
<td>$51.1</td>
<td>$52.89</td>
<td>$880.00</td>
<td>$105.7K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/16/24</td>
<td>$41.3</td>
<td>$37.7</td>
<td>$40.13</td>
<td>$880.00</td>
<td>$77.7K</td>
<td style="text-align: right;">43</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$54.1</td>
<td>$52.2</td>
<td>$54.1</td>
<td>$950.00</td>
<td>$54.1K</td>
<td style="text-align: right;">41</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/26/24</td>
<td>$19.0</td>
<td>$19.0</td>
<td>$19.0</td>
<td>$910.00</td>
<td>$39.9K</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">26</td>
</tr>
</tbody>
</table>

<h3>About Regeneron Pharmaceuticals</h3>
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
<h3>Where Is Regeneron Pharmaceuticals Standing Right Now?</h3>
<ul>
<li>With a volume of 198,184, the price of REGN is down -1.73% at $920.0. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 21 days.</li>
</ul>
<h3>Expert Opinions on Regeneron Pharmaceuticals</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $1143.5.
<ul>
<li>Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Regeneron Pharmaceuticals with a target price of $1135. </li>
<li>An analyst from Truist Securities persists with their Buy rating on Regeneron Pharmaceuticals, maintaining a target price of $1135. </li>
<li>An analyst from RBC Capital downgraded its action to Outperform with a price target of $1189. </li>
<li>Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on Regeneron Pharmaceuticals with a target price of $1115. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Regeneron Pharmaceuticals with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking

RBC Capital analyst Brian Abrahams reiterates Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Outperform and maintains $1189 price target.

RBC Capital Reiterates Outperform on Regeneron Pharmaceuticals, Maintains $1189 Price Target

With an 11-month median duration of follow up, the linvoseltamab data among 117 patients presented at AACR reinforce the strength of previously shared findings and included a:
<ul>
<li>71%&nbsp;objective response rate (ORR), with&nbsp;46%&nbsp;of patients achieving a complete response (CR) or better and&nbsp;62%&nbsp;achieving a very good partial response (VGPR) or better, as determined by an independent review committee.</li>
<li>1-month median time to response&nbsp;(range: &lt;1-6 months). In responders, the median time to a VGPR or better was 3 months (range: &lt;1-13 months) and to a CR or better was 8 months (range: 2-14 months).</li>
<li>Median duration of response (DoR), median progression-free survival (PFS) and median overall survival (OS) were not reached. At 12 months, the estimated probability of maintaining a response was&nbsp;78%, being progression free was&nbsp;69%&nbsp;and survival was&nbsp;75%.</li>
<li>Among patients who had a CR or better and were minimum residual disease (MRD) evaluable,&nbsp;93%&nbsp;(25 of 27 patients) were MRD negative at 10-5.</li>
</ul>

Reported Sunday, Regeneron Pharmaceuticals Presented Pivotal Data On Linvoseltamab At AACR 2024, Reinforcing A High Response Rate That Deepens Over Time In Patients With Heavily Pre-Treated Multiple Myeloma

Truist Securities analyst Robyn Karnauskas maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Buy and maintains $1135 price target.

Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Maintains $1135 Price Target

Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) has outperformed the market over the past 10 years by 1.97% on an annualized basis producing an average annual return of 12.9%. Currently, Regeneron Pharmaceuticals has a market capitalization of $105.76 billion. 
Buying $100 In REGN: If an investor had bought $100 of REGN stock 10 years ago, it would be worth $335.50 today based on a price of $963.51 for REGN at the time of writing.
<h3>Regeneron Pharmaceuticals's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1711999833_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today

Deep-pocketed investors have adopted a bullish approach towards Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in REGN usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Regeneron Pharmaceuticals. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 50% bearish. Among these notable options, 3 are puts, totaling $182,250, and 5 are calls, amounting to $358,256.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $930.0 to $1260.0 for Regeneron Pharmaceuticals over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Regeneron Pharmaceuticals stands at 69.83, with a total volume reaching 89.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Regeneron Pharmaceuticals, situated within the strike price corridor from $930.0 to $1260.0, throughout the last 30 days.
<h3>Regeneron Pharmaceuticals 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1711647935_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$159.9</td>
<td>$153.0</td>
<td>$157.64</td>
<td>$1000.00</td>
<td>$157.6K</td>
<td style="text-align: right;">71</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/03/24</td>
<td>$16.0</td>
<td>$14.4</td>
<td>$16.0</td>
<td>$930.00</td>
<td>$80.0K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$163.9</td>
<td>$159.5</td>
<td>$159.5</td>
<td>$1000.00</td>
<td>$79.7K</td>
<td style="text-align: right;">71</td>
<td style="text-align: right;">15</td>
</tr>
<tr>
<td>REGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$121.6</td>
<td>$118.9</td>
<td>$118.9</td>
<td>$1000.00</td>
<td>$59.4K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
</tr>
<tr>
<td>REGN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$80.9</td>
<td>$74.2</td>
<td>$75.6</td>
<td>$1040.00</td>
<td>$52.9K</td>
<td style="text-align: right;">295</td>
<td style="text-align: right;">7</td>
</tr>
</tbody>
</table>

<h3>About Regeneron Pharmaceuticals</h3>
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Having examined the options trading patterns of Regeneron Pharmaceuticals, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Regeneron Pharmaceuticals Standing Right Now?</h3>
<ul>
<li>With a volume of 160,144, the price of REGN is down 0.0% at $966.3. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 35 days.</li>
</ul>
<h3>What The Experts Say On Regeneron Pharmaceuticals</h3>
In the last month, 4 experts released ratings on this stock with an average target price of $1125.0.
<ul>
<li>In a cautious move, an analyst from Bernstein downgraded its rating to Outperform, setting a price target of $1125. </li>
<li>An analyst from Truist Securities persists with their Buy rating on Regeneron Pharmaceuticals, maintaining a target price of $1135. </li>
<li>An analyst from Morgan Stanley has decided to maintain their Overweight rating on Regeneron Pharmaceuticals, which currently sits at a price target of $1115. </li>
<li>Reflecting concerns, an analyst from Bernstein lowers its rating to Outperform with a new price target of $1125.</li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Regeneron Pharmaceuticals options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends

12 analysts have expressed a variety of opinions on Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $1068.58, along with a high estimate of $1184.00 and a low estimate of $850.00. Observing a 3.16% increase, the current average has risen from the previous average price target of $1035.86. 
<img src="https://www.benzinga.com/files/images/story/2024/1711461671_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Regeneron Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robyn Karnauskas</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$1135.00</td>
<td>$1135.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1115.00</td>
<td>$1104.00</td>
</tr>
<tr>
<td>William Pickering</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$1125.00</td>
<td>-</td>
</tr>
<tr>
<td>Aaron Gal</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$1125.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1184.00</td>
<td>$1096.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$925.00</td>
<td>$850.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1110.00</td>
<td>$1076.00</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$1082.00</td>
<td>$1055.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$1076.00</td>
<td>-</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1020.00</td>
<td>$935.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$1076.00</td>
<td>-</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$850.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Regeneron Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Regeneron Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Regeneron Pharmaceuticals's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Regeneron Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/REGN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Regeneron Pharmaceuticals analyst ratings.</a>
<h2>All You Need to Know About Regeneron Pharmaceuticals</h2>
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
<h3>A Deep Dive into Regeneron Pharmaceuticals's Financials</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Regeneron Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 0.58%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Regeneron Pharmaceuticals's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 33.77%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Regeneron Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 4.56%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Regeneron Pharmaceuticals's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 3.55%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Regeneron Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.1, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on Regeneron (REGN – Research Report), with a price targ...

Regeneron (REGN) Gets a Buy from Piper Sandler

Additions and deletions of Oppenheimer's OPCO Trifecta

Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of...

Wells Fargo Reaffirms Their Buy Rating on Regeneron (REGN)

Regeneron, Mammoth in pact to develop CRISPR-based gene editing therapies

AbbVie reports positive results from Rinoq versus Dupixent study

AbbVie reports positive results from Rinvoq versus Dupixent study

These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)

In a report released today, Carter Gould from Barclays maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of $1,050...

Barclays Sticks to Their Buy Rating for Regeneron (REGN)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGN – Research Report), Gilead Sciences ...

Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Gilead Sciences (GILD)

ADAP

ADSK

APLM

APLMW

ASPHF

AUTL

BEIGF

BGNE

BMYMP

BRZE

CARR

CRTHF

DAWN

DCPH

DMPWW

DSKYF

DSNKY

DXCM

ENSG

ESTC

GILD

GLAXF

INCY

IOVA

JBPHF

KNSA

KTRA

LULU

MDNAF

MPSYF

MSCI

NVCR

NVSEF

OKTA

POOL

RCUS

RHHBF

RHHBY

RHHVF

SMMT

SNYNF

SPHRF

SPHRY

SRRK

TEAM

TKPHF

ULTA

Press Releases

Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey

Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024

Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors

REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Regeneron Stockholders and Encourages Investors to Contact the Firm